CagriSemavsPemvidutide

CagriSema exploits the principle that the brain's appetite regulation system has multiple independent signaling pathways, and targeting two of them simultaneously produces weight loss greater than either alone. The semaglutide component activates GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem, suppressing hunger through POMC neuron activation and NPY/AgRP neuron inhibition, while also slowing gastric emptying and improving glycemic control.

The cagrilintide component activates amylin receptors (CTR/RAMP complexes) in the area postrema and lateral parabrachial nucleus — brain regions that form a parallel but distinct satiety circuit. Amylin receptor signaling reduces meal size by promoting early satiation, whereas GLP-1 signaling primarily reduces between-meal hunger and food cravings. Together, they address both the desire to eat and the amount consumed per meal.

At the metabolic level, both components enhance insulin secretion and suppress glucagon in a glucose-dependent manner, but through separate pancreatic receptor populations. The combination also produces synergistic effects on gastric emptying, further reducing postprandial glucose spikes. Phase 3 trial data showed approximately 25% body weight loss — among the highest recorded for any pharmaceutical intervention — with the combination significantly outperforming either component alone, validating the dual-pathway hypothesis.

Pemvidutide (ALT-801) is a once-weekly subcutaneous dual GLP-1 and glucagon receptor agonist, mechanistically similar to mazdutide and survodutide but with a distinct molecular design and a primary development focus on metabolic dysfunction-associated steatohepatitis (MASH) alongside obesity. The dual mechanism combines appetite suppression with enhanced energy expenditure and direct hepatic fat mobilisation.

The GLP-1 receptor component drives the established central appetite suppression through hypothalamic and brainstem signalling, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The glucagon receptor agonism component is what differentiates pemvidutide from pure GLP-1 drugs — glucagon binding in hepatocytes activates adenylyl cyclase and protein kinase A, driving up fatty acid beta-oxidation and ketogenesis while reducing de novo lipogenesis. This directly mobilises stored hepatic triglycerides for energy use rather than continued storage, addressing the core pathology of MASH. In adipose tissue and beyond, glucagon signalling also raises whole-body energy expenditure through thermogenic and futile-cycle mechanisms.

The receptor potency ratio is balanced so that glucagon-driven hepatic glucose output is offset by GLP-1-driven insulinotropic effects, yielding net glycemic improvement alongside enhanced fat oxidation. Phase 2b results in obesity demonstrated approximately 15.6% mean body weight loss at 48 weeks, and parallel MASH trials showed significant reductions in liver fat content alongside improvements in fibrosis markers. Phase 3 trials in both obesity and MASH are now underway, positioning pemvidutide as Altimmune's lead asset and a competitor to mazdutide and survodutide in the dual GLP-1/glucagon class.